JPY 84.0
(-3.45%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 959 Million JPY | -17.28% |
2022 | 1.15 Billion JPY | 8.28% |
2021 | 1.06 Billion JPY | -14.04% |
2020 | 1.24 Billion JPY | -30.74% |
2019 | 1.79 Billion JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 179.97 Million JPY | 2.21% |
2024 Q1 | 176.07 Million JPY | -30.01% |
2023 Q4 | 251.57 Million JPY | 17.36% |
2023 FY | 956 Million JPY | -17.28% |
2023 Q3 | 214.35 Million JPY | 16.71% |
2023 Q2 | 183.66 Million JPY | -38.68% |
2023 Q1 | 299.53 Million JPY | -43.15% |
2022 Q4 | 526.84 Million JPY | 123.14% |
2022 FY | 1.15 Billion JPY | 8.28% |
2022 Q3 | 236.09 Million JPY | 0.0% |
2021 FY | 1.06 Billion JPY | -14.04% |
2020 FY | 1.24 Billion JPY | -30.74% |
2019 FY | 1.79 Billion JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 97.802% |
Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.963% |
Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.823% |
Shionogi & Co., Ltd. | 197.62 Billion JPY | 99.515% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 74.333% |
Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 98.539% |
Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 96.696% |
Eisai Co., Ltd. | 533.01 Billion JPY | 99.82% |
Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 81.844% |
Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 98.543% |
Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 97.927% |
Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 91.699% |
Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 88.35% |
Tsumura & Co. | 48.8 Billion JPY | 98.035% |
Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 97.122% |
Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 95.091% |
Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 98.495% |
Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 92.423% |
Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 97.63% |
KYORIN Holdings, Inc. | 45.39 Billion JPY | 97.887% |
Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 76.93% |
Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 83.869% |
SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 81.638% |
Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | 66.629% |
Solasia Pharma K.K. | 1.47 Billion JPY | 35.027% |
Modalis Therapeutics Corporation | 2.37 Billion JPY | 59.547% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 96.031% |
Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 97.293% |
Cyfuse Biomedical K.K. | 735.18 Million JPY | -30.444% |
Toho Holdings Co., Ltd. | 99.81 Billion JPY | 99.039% |
Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | 57.515% |